ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Salbutamol significantly increases cerebral perfusion in proof-of-concept trial
March 17, 2021In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease. -
CuraSen doses first subjects in phase 1 trial of CST-2032
September 18, 2020CuraSen Therapeutics announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.
Pharma Sources Insight January 2025
